Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 6/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 5/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153240 | 0.88 | NAPEPLD (0.33) | PIK3R1RAF1PIK3CAMTORBRAF | |
| SCHEMBL19686800 | 0.80 | KMT2A (0.41) | ATRPIK3R1PIK3CAGPR119KIF18A | |
| SCHEMBL19686799 | 0.79 | RAF1 (0.38) | ATRRAF1PIK3CAMTORBRAF | |
| SCHEMBL19687233 | 0.79 | GPR119 (0.44) | ATRPIK3CAPIK3CBGPR119KIF18A | |
| SCHEMBL19686846 | 0.79 | ATR (0.34) | ATRPIK3R1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL19687466 | 0.75 | PIK3R2 (0.32) | ATRRAF1BRAFPIK3CDGPR119 | |
| SCHEMBL19687205 | 0.75 | IDH1 (0.32) | — | |
| SCHEMBL19687203 | 0.75 | IDH1 (0.34) | — | |
| SCHEMBL21144017 | 0.75 | P2RX3 (0.36) | RAF1BRAF | |
| SCHEMBL21166046 | 0.75 | IDH1 (0.40) | RAF1BRAFGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-20210380571-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3571193-B1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10717728-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-11-21 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-10351553-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2018-08-02 | — | — | US | disclosed |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2018-08-02 | — | — | US | disclosed |
| WO-2018136917-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-9975886-B1 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975886-B1 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ATR 4491/4885PIK3R1 1998/4885DRD2 4052/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | ATR 4491/4885PIK3R1 1998/4885DRD2 4052/4885 |
| US-20210380571-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | ATR 4567/4885PIK3R1 3120/4885DRD2 3858/4885 |
| US-10717728-B2 | Potassium channel modulators | KCNJ2, KCNQ2, KCNJ1 | ATR 4446/4885PIK3R1 3143/4885DRD2 3802/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ATR 4491/4885PIK3R1 1998/4885DRD2 4052/4885 |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | ATR 4567/4885PIK3R1 3120/4885DRD2 3858/4885 |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | ATR 4567/4885PIK3R1 3120/4885DRD2 3858/4885 |
| US-10351553-B2 | Potassium channel modulators | KCNN2, KCNN1, KCNN3 | ATR 3586/4885PIK3R1 2061/4885DRD2 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.